HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma

Prognostic and predictive markers utilized in invasive breast carcinoma are limited and include ER, PR, Ki67, and ERBB2 (HER2). In the case of HER2, over-expression or amplification serves as eligibility for anti-HER2 based therapy, including trastuzumab (Herceptin®, Genentech). While clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Portier, Bryce P, Minca, Eugen C, Wang, Zhen, Lanigan, Christopher, Gruver, Aaron M, Downs-Kelly, Erinn, Budd, G Thomas, Tubbs, Raymond R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2013
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858553/
https://www.ncbi.nlm.nih.gov/pubmed/24091566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3858553/
https://www.ncbi.nlm.nih.gov/pubmed/24091566

Ejemplares similares